Investigation of the effect of pentoxifylline in the treatment of leishmaniasis

Investigation and comparison of the effect of intralesional injection of pentavalent antimony and placebo with intralesional injection of pentavalent antimony and pentoxifylline in patients with rural cutaneous leishmaniasis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251211068289N2

Enrollment

Registered

2026-01-24

Start date

2025-12-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Intervention group: The group treated with intralesional injections of antimony ampule (Glucantime) (Couble Darou manufactory) an ampule daily for one month and oral pentoxifylline (Fa

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Infected with cutaneous leishmaniasis of the rural type. Candidate for intralesional injection of Glucantime Age over 18 years

Exclusion criteria

Exclusion criteria: History of sensitivity to Glucantime History of sensitivity to pentoxifylline Lack of consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Diameter of induration. Timepoint: Before the intervention, at the time of completion of the intervention, and 3 months after the completion of the intervention. Method of measurement: Dermoscopy.;Color of lesion. Timepoint: Before the intervention, at the time of completion of the intervention, and 3 months after the completion of the intervention. Method of measurement: clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZabihollah Shahmoradi

Esfahan University of Medical Sciences

Shahmoradi@med.mui.ac.ir+98 31 3822 2563

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026